RG6189 / Roche - LARVOL DELTA

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. (PubMed, Nat Cancer) - P1 | "In summary, treatment with a tumor-targeted CD40 agonist antibody is feasible, clinically manageable and induces immunomodulation of the tumor microenvironment. ClinicalTrials.gov registration: NCT04857138 ."

First-in-human • Journal • P1 data • Immunology • Oncology • Solid Tumor • CD40 • LAMP3

Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment (ESMO 2024) - P1, P1/2, P1b, P1b/2a, P2 | "In summary, targeting CD40 agonism to the tumour achieved a strong and sustained target engagement and tumour tissue immunomodulation with a favourable safety profile at all tested doses, supporting further studies in combination with other anti-cancer agents in earlier lines of treatment."

Biomarker • IO biomarker • Tumor microenvironment • Oncology • Solid Tumor • CD40 • FAP • LAMP3

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Hoffmann-La Roche | Recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors (SITC 2023) - P1 | "In summary, targeting CD40 agonism to the tumor has led to a favorable safety profile at doses with strong and sustained target engagement, and supports further studies in combination with other anti-cancer therapies. The patients and their families The study investigators and members of the clinical study teams."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • CD40 • FAP